Omalizumab improves angioedema-related quality of life impairment in chronic spontaneous urticaria patients: Results from the X-ACT study

被引：0
|
作者：
Weller, Karsten [1 ]
Staubach, Petra [2 ]
Metz, Martin [1 ]
Chapman-Rothe, Nadine [3 ]
Sieder, Christian [3 ]
Brautigam, Matthias [3 ]
Maurer, Marcus [1 ]
机构：
[1] Charite Univ Med Berlin, Dept Dermatol & Allergy, Berlin, Germany
[2] Univ Med Ctr, Dept Dermatol, Utrecht, Netherlands
[3] Novartis Pharmaceut, Basel, Switzerland
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2018年 / 79卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
6835
引用
收藏
页码：AB209 / AB209
页数：1
相关论文
共 50 条
  • [31] Dupilumab Improves Urticaria-Specific Quality of Life in Patients with Chronic Spontaneous Urticaria Uncontrolled by H1 Antihistamines
    Maurer, Marcus
    Casale, Thomas
    Yosipovitch, Gil
    Saini, Sarbjit
    Ben-Shoshan, Moshe
    Beck, Lisa
    Msihid, Jerome
    Sugerman, Philip
    Cyr, Sonya
    Thomas, Ryan
    Chuang, Chien-Chia
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB2 - AB2
  • [32] Omalizumab Improves Quality of Life (QoL) in Patients with Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU) As Assessed By the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL): A Post-Hoc Analysis of Percent Change from Baseline to Week 12
    Janssens, Nico
    Maurer, Marcus
    Khalil, Sam
    Balp, Maria-Magdalena
    Rosen, Karin
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB132 - AB132
  • [33] Efficacy and safety of omalizumab in Japanese and Korean patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): Results from the phase III POLARIS study
    Hide, Michihiro
    Park, Hae-Sim
    Igarashi, Atsuyuki
    Ye, Young Min
    Kim, Tae-Bum
    Yagami, Akiko
    Lee, Jae-Hyun
    Fukunaga, Atsushi
    Khalil, Sam
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB112 - AB112
  • [34] Risk factors of quality-of-life and sexual function impairment in chronic spontaneous urticaria patients: cross-sectional study.
    Sanchez-Diaz, Manuel
    Salazar-Nievas, Maria Carmen
    Molina-Leyva, Alejandro
    Arias-Santiago, Salvador
    DERMATOLOGY, 2023, 239 (04) : 601 - 608
  • [35] Real-life study of patients treated with omalizumab for chronic spontaneous urticaria in France: 6-month data of the LUCIOL study
    Barbaud, A.
    Staumont-Salle, D.
    Bouillet, L.
    Vicaut, E.
    Tetart, F.
    Azib-Meftah, S.
    Milpied, B.
    Fougerousse, A.
    Karine, B.
    Pelvet, B.
    Le Guen, S.
    Berard, F.
    ALLERGY, 2019, 74 : 115 - 116
  • [36] Angioedema with and without wheals in patients with chronic spontaneous urticaria: Findings from the worldwide prospective observational aware study
    Maurer, M.
    Houghton, K.
    Berroa, F.
    Ensina, L. F.
    Guillet, G.
    Labrador, M.
    Gimenez-Arnau, A. M.
    Marsland, A.
    Rossi, O.
    Velasco, M.
    Chapman-Rothe, N.
    ALLERGY, 2018, 73 : 23 - 24
  • [37] 'It has given me my life back': a qualitative study exploring the lived experience of patients with chronic spontaneous urticaria on omalizumab
    Porter, Emma
    Tierney, Emma
    Byrne, Berbie
    Basheer-O'Dwyer, Sarah
    Kanaan, Ansam
    Ramsay, Bart
    Field, Sinead
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2022, 47 (11) : 2032 - 2034
  • [38] Effect of omalizumab over a 6-month treatment period on angioedema and quality of life associated with refractory chronic idiopathic/spontaneous urticaria (CIU/CSU): subgroup analyses focused on the presence of baseline angioedema
    Maurer, M.
    Spector, S.
    Bernstein, J.
    Gabriel, S.
    Karagiannis, T.
    Kianifard, F.
    Mendelson, M.
    ALLERGY, 2015, 70 : 592 - 592
  • [39] Lanadelumab improves health-related quality of life in patients with hereditary Angioedema (HAE): findings from the HELP study
    Longhurst, Hilary
    Lumry, William
    Weller, Karsten
    Magerl, Markus
    Lu, Peng
    Jain, Gagan
    Lewis, Hannah
    Maurer, Marcus
    CLINICAL AND EXPERIMENTAL ALLERGY, 2018, 48 (11): : 1524 - 1525
  • [40] Omalizumab Improves Quality of Life (QoL) in Patients with Refractory Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU) As Assessed By the Dermatology Life Quality Index (DLQI): A Post-Hoc Analysis of Percent Change from Baseline to Week 12
    Rosen, Karin
    Khalil, Sam
    Balp, Maria-Magdalena
    Maurer, Marcus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB127 - AB127
12345